Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MGLL | Q99685 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.52 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.52 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.52 |
| ▸ | PRKCA | P17252 | 1/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20262144 | 1.00 | DGKA (0.55) | DGKAFAAHTSHRMGLLMAPT | |
| SCHEMBL24588632 | 0.95 | DGKA (0.57) | DGKAFAAHTSHRMAPTPRKCE | |
| SCHEMBL21461637 | 0.95 | DGKA (0.57) | DGKAFAAHTSHRMAPTPRKCE | |
| SCHEMBL31376706 | 0.95 | DGKA (0.57) | DGKAFAAHTSHRMAPTPRKCE | |
| SCHEMBL25285196 | 0.95 | DGKA (0.57) | DGKAFAAHTSHRMAPTPRKCE | |
| SCHEMBL25239451 | 0.95 | DGKA (0.57) | DGKAFAAHTSHRMAPTPRKCE | |
| SCHEMBL20262175 | 0.95 | DGKA (0.57) | DGKAFAAHTSHRMAPTPRKCE | |
| SCHEMBL24588792 | 0.95 | DGKA (0.57) | DGKAFAAHTSHRMAPTPRKCE | |
| SCHEMBL20500791 | 0.95 | DGKA (0.57) | DGKAFAAHTSHRMAPTPRKCE | |
| SCHEMBL31024466 | 0.95 | DGKA (0.57) | DGKAFAAHTSHRMAPTPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637422-B2 | Ionizable cationic lipid for RNA delivery | ARCTURUS THERAPEUTICS, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260131020-A1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | ARCTURUS THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12527881-B2 | Ionizable cationic lipid for RNA delivery | ARCTURUS THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4678629-A1 | IONIZABLE LIPID MOLECULE, PREPARATION METHOD THEREFOR AND USE THEREOF | Maxirna (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| EP-4527831-A2 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | Arcturus Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2024183821-A1 | IONIZABLE LIPID MOLECULE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海吉量医药工程有限公司 | 2024-09-12 | — | — | WO | disclosed |
| EP-4310075-A2 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | Arcturus Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-3558943-B1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | ARCTURUS THERAPEUTICS INC (US) | 2023-10-18 | — | — | EP | disclosed |
| EP-3558942-B1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | ARCTURUS THERAPEUTICS INC (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-114917203-A | Ionizable cationic lipids for RNA delivery | 阿克丘勒斯治疗公司 | 2022-08-19 | — | — | CN | disclosed |
| US-10980895-B2 | Ionizable cationic lipid for RNA delivery | ARCTURUS THERAPEUTICS, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-10961188-B2 | Ionizable cationic lipid for RNA delivery | ARCTURUS THERAPEUTICS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200109113-A1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2020-04-09 | — | — | US | disclosed |
| EP-3558942-A1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | Arcturus Therapeutics, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| EP-3558943-A1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | Arcturus Therapeutics, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-10383952-B2 | Ionizable cationic lipid for RNA delivery | ARCTURUS THERAPEUTICS, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| WO-2018118102-A1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018119163-A1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | PAYNE JOSEPH E (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180169268-A1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180170866-A1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109113-A1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | RNASEH1, RNASE1, HNRNPA1 | DGKA 3178/4885FAAH 1713/4885TSHR 941/4885 |
| US-10961188-B2 | Ionizable cationic lipid for RNA delivery | RNASEH1, RNASE1, HNRNPA1 | DGKA 3178/4885FAAH 1713/4885TSHR 941/4885 |
| US-10980895-B2 | Ionizable cationic lipid for RNA delivery | RNASEH1, RNASE1, HNRNPA1 | DGKA 3301/4885FAAH 1861/4885TSHR 817/4885 |
| US-10383952-B2 | Ionizable cationic lipid for RNA delivery | RNASEH1, RNASE1, HNRNPA1 | DGKA 3267/4885FAAH 1854/4885TSHR 833/4885 |
| US-20260131020-A1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | SLC27A1, NSUN3, SLC10A1 | DGKA 1557/4885FAAH 1291/4885TSHR 1345/4885 |
| US-20180170866-A1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | RNASEH1, RNASE1, HNRNPA1 | DGKA 3187/4885FAAH 1465/4885TSHR 922/4885 |
| US-20180169268-A1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | RNASEH1, RNASE1, HNRNPA1 | DGKA 3267/4885FAAH 1854/4885TSHR 833/4885 |
| US-12637422-B2 | Ionizable cationic lipid for RNA delivery | POLRMT, SLC27A1, SLC43A1 | DGKA 1447/4885FAAH 890/4885TSHR 1630/4885 |
| US-12527881-B2 | Ionizable cationic lipid for RNA delivery | NSUN3, SLC27A1, SLC43A1 | DGKA 1921/4885FAAH 1373/4885TSHR 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.